The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04789616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT04789616
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT04789616. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-15 (actual); primary completion 2025-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
- Acronym
- CAMAROS
- Condition
- Stroke
- Intervention (Drug)
- Maraviroc
- Intervention (Behavioral)
- Exercise Program
- Intervention (Other)
- Placebo
- Intervention (Device)
- Activity Sensor
- Intervention (Behavioral)
- Motor Learning
- Lead sponsor
- University of Calgary
- Collaborator
- University Health Network, Toronto
- Collaborator
- University of California, Los Angeles
- Collaborator
- Sunnybrook Health Sciences Centre
- Collaborator
- University of British Columbia
- Collaborator
- Memorial University of Newfoundland
- Collaborator
- Dalhousie University
- Collaborator
- Parkwood Hospital, London, Ontario
- Collaborator
- Riverview Health Centre Foundation
- Collaborator
- The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Record details
- Record id
cardio:ct-nct04789616- Content hash
25a1e2bb1a1c215ca4ff15cb4db263df72e539fcb012ab5b57f1c3b28b533f1f